We are an Australian company specialising in the commercialisation of tests for solid tumors in cancers such as prostate, bladder and pancreatic. We have a comprehensive intellectual property portfolio to help improve patient outcomes.

MiCheck® Prostate is now available in the US and Australia

Expert Opinion on Need for Biomarker Panels in Biopsy Decisions

Neal D. Shore, MD, FACS presented abstract 229 regarding the current need for a more accurate test to identify patients for prostate biopsy at the 2022 ASCO Genitourinary Cancers Symposium.

The Unmet Need for a Biomarker to Support Imaging

Professor Mark Emberton OBE, University College London, on his study that aims to improve the current prostate specific antigen (PSA)/biopsy risk stratification for prostate cancer (PCa) and develop a new image-based method with biomarkers like the MiCheck® Prostate for determining high/low risk PCa in men.

MiCheck® Prostate

MiCheck® Prostate is for male subjects being considered by physicians for a prostate biopsy.

It is intended to supplement and not replace the significance of other clinical factors or test results which collectively assist the clinical judgement and experience of the urologist in the decision about whether or not to proceed to prostate biopsy.

Prostate biopsy is required for the diagnosis of cancer.

MiCheck® Prostate offers:
Ease of use – blood collection made at the same time as the blood draw for a PSA test.
No interruption to the clinician’s current workflow.
Clear clinical utility – single page well-defined report to assist the clinical judgement and experience of the urologist in the decision about whether or not to proceed to prostate biopsy .
Timely delivery of results – ready for the patient’s next visit to the clinician.
Dominant health economics in comparison to standard of care.
Currently available in USA and Australia.

Achievements

N

2023

N

US reimbursement confirmed.

N

MiCheck® Prostate test is available through Douglass Hanly Moir laboratories in Australia.

N

2022

N

December: US – Minomic Inc. received Medicare Registration.
AU – Completed Minomic API/Sonic IT reporting integration.

N

October: US – Minomic Inc. received first commercial samples.

N

September: US – Minomic US CLIA lab received Maryland State Registration. QMS implantation completed.
AU – Minomic completed Australian clinical validation study at Macquarie University Hospital.

N

May AU – Completed analytical validation with Sonic DHM.

N

April US – Minomic Inc. received US CLIA Lab Registration.

N

2021

N

Minomic International Limited establishes commercial partnership with 20/20 GeneSystems to offer MiCheck® Prostate in the USA.

N

Minomic enters into collaboration with GloriousMed to introduce MiCheck® Prostate into China.

N

Laboratory Developed MiCheck® Prostate Cancer Test Roll-out.

N

2020

N

MiCheck® Pancreatic Cancer Study Commenced.

N

2018

N

Completed MiCheck® Prostate Cancer Prospective Trial.

Find Out More Information

  • About our highly effective prostate cancer test >More
  • About how your company and Minomic could partner to deliver better prostate cancer diagnostics >More 

10 + 1 =

Copyright © 2023 Minomic®